Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia

被引：8
|
作者：
Allen, Steven L. [1 ]
Kolitz, Jonathan E. [2 ]
Lundberg, Ante S. [3 ]
Bennett, John M. [4 ]
Capizzi, Robert L. [3 ]
Budman, Daniel R. [2 ]
机构：
[1] N Shore Univ Hosp, Albert Einstein Coll Med, Monter Canc Ctr, Lake Success, NY 11042 USA
[2] New York Univ, N Shore Univ Hosp, Monter Canc Ctr, Sch Med, Lake Success, NY USA
[3] Antisoma, Cambridge, MA USA
[4] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA
来源：
LEUKEMIA RESEARCH | 2010年 / 34卷 / 04期
关键词：
AML; Phase I; P-glycoprotein; Pgp; Multidrug resistance; SOUTHWEST-ONCOLOGY-GROUP; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; MYELODYSPLASTIC-SYNDROME; POSTREMISSION THERAPY; ANTITUMOR-ACTIVITY; ELDERLY-PATIENTS; GROUP-B; CANCER; INDUCTION;
D O I：
10.1016/j.leukres.2009.07.038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Amonafide-L-malate ( amonafide) is a unique DNA intercalator that maintains activity in the presence of MDR mechanisms, a frequent cause of treatment-failure in secondary AML. 43 patients with relapsed/refractory or secondary AML or CML blast crisis were enrolled into two phase I dose-escalation studies investigating amonafide as monotherapy or in combination with cytarabine. 3/17 patients in the monotherapy trial and 10/26 patients in the combination trial achieved a complete remission. Between both trials responses occurred in 9/20 patients with secondary AML. Both trials demonstrated an acceptable safety profile and significant antileukemic activity in patients with poor-risk AML, especially those with secondary AML. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码：487 / 491
页数：5
相关论文
共 50 条
  • [31] A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
    Wang, Amy Y.
    Weiner, Howard
    Green, Margaret
    Chang, Hua
    Fulton, Noreen
    Larson, Richard A.
    Odenike, Olatoyosi
    Artz, Andrew S.
    Bishop, Michael R.
    Godley, Lucy A.
    Thirman, Michael J.
    Kosuri, Satyajit
    Churpek, Jane E.
    Curran, Emily
    Pettit, Kristen
    Stock, Wendy
    Liu, Hongtao
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11 : 4
  • [32] Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials
    Schlenk, Richard F.
    Krauter, Juergen
    Raffoux, Emmanuel
    Kreuzer, Karl-Anton
    Schaich, Markus
    Noens, Lucien
    Pabst, Thomas
    Vusirikala, Madhuri
    Bouscary, Didier
    Spencer, Andrew
    Candoni, Anna
    Gil, Jorge Sierra
    Berkowitz, Noah
    Weber, Hans-Jochen
    Ottmann, Oliver
    HAEMATOLOGICA, 2018, 103 (01)
  • [33] A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
    Amy Y. Wang
    Howard Weiner
    Margaret Green
    Hua Chang
    Noreen Fulton
    Richard A. Larson
    Olatoyosi Odenike
    Andrew S. Artz
    Michael R. Bishop
    Lucy A. Godley
    Michael J. Thirman
    Satyajit Kosuri
    Jane E. Churpek
    Emily Curran
    Kristen Pettit
    Wendy Stock
    Hongtao Liu
    Journal of Hematology & Oncology, 11
  • [34] Mutational Signature Correlates with Proliferative Phenotype in NCCN Poor-Risk Acute Myeloid Leukemia
    Shaver, Aaron C.
    Juskevictus, Ridas
    Dabei, Robert D.
    Strickland, Stephen A.
    Ferrell, Paul B.
    Byrne, Michael
    Mohan, Sanjay R.
    Vnencak-Jones, Cindy L.
    Zutter, Mary M.
    Kim, Annette S.
    Seegmiller, Adam
    Savona, Michael R.
    Head, David R.
    LABORATORY INVESTIGATION, 2017, 97 : 377A - 377A
  • [35] Mutational Signature Correlates with Proliferative Phenotype in NCCN Poor-Risk Acute Myeloid Leukemia
    Shaver, Aaron C.
    Juskevicius, Ridas
    Dabei, Robert D.
    Strickland, Stephen A.
    Ferrell, Paul B.
    Byrne, Michael
    Mohan, Sanjay R.
    Vnencak-Jones, Cindy L.
    Zutter, Maly M.
    Kim, Annette S.
    Seegmiller, Adam
    Savona, Michael R.
    Head, David R.
    MODERN PATHOLOGY, 2017, 30 : 377A - 377A
  • [36] A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients
    Hui-Jen Tsai
    Shih Sheng Jiang
    Wen-Chun Hung
    Gautam Borthakur
    Sheng-Fung Lin
    Naveen Pemmaraju
    Elias Jabbour
    John S. Bomalaski
    Ya-Ping Chen
    Hui-Hua Hsiao
    Ming-Chung Wang
    Ching-Yuan Kuo
    Hung Chang
    Su-Peng Yeh
    Jorge Cortes
    Li-Tzong Chen
    Tsai-Yun Chen
    Scientific Reports, 7
  • [37] A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients
    Tsai, Hui-Jen
    Jiang, Shih Sheng
    Hung, Wen-Chun
    Borthakur, Gautam
    Lin, Sheng-Fung
    Pemmaraju, Naveen
    Jabbour, Elias
    Bomalaski, John S.
    Chen, Ya-Ping
    Hsiao, Hui-Hua
    Wang, Ming-Chung
    Kuo, Ching-Yuan
    Chang, Hung
    Yeh, Su-Peng
    Cortes, Jorge
    Chen, Li-Tzong
    Chen, Tsai-Yun
    SCIENTIFIC REPORTS, 2017, 7
  • [38] LENALIDOMIDE PHARMACOKINETICS IN COMBINATION WITH IDARUBION AND CYTARABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA.
    Jiang, Y.
    Wang, J.
    Walker, A.
    Li, X.
    Drake, A.
    Schaaf, L.
    Byrd, J.
    Marcucci, G.
    Grever, M.
    Blum, W.
    Phelps, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S66 - S67
  • [39] Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia
    Attar, Eyal C.
    De Angelo, Daniel J.
    Supko, Jeffrey G.
    D'Amato, Ferdinando
    Zahrieh, David
    Sirulnik, Andres
    Wadleigh, Martha
    Ballen, Karen K.
    McAfee, Steve
    Miller, Kenneth B.
    Levine, James
    Galinsky, Ilene
    Trehu, Elizabeth G.
    Schenkein, David
    Neuberg, Donna
    Stone, Richard M.
    Amrein, Philip C.
    CLINICAL CANCER RESEARCH, 2008, 14 (05) : 1446 - 1454
  • [40] A Phase I Study of Lenalidomide and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
    Griffiths, Elizabeth A.
    Brady, William
    Tan, Wei
    Vigil, Carlos E.
    Thompson, James E.
    Ford, Laurie A.
    Dickey, Noelle M.
    Sperrazza, Jill
    Wang, Eunice S.
    Wetzler, Meir
    BLOOD, 2014, 124 (21)
12345